A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
Ryan Scott
Advertisement
Articles by Ryan Scott
Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
AI Chatbots Score Below 28% on Colorectal Cancer Questions
2
5 Notable FDA Approvals From the First Half of 2026
3
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
4
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
5